Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Solid Neoplasms 1SCLC 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Solid Tumors 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × Platinum × Clear all
NCT00122460 2014-07-23

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
442 enrolled 18 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡